Form 4: Akero Therapeutics Executive Patrick Lamy Reports Stock Transactions

Senior VP of Commercial Strategy at Akero Therapeutics, Patrick Lamy, reports the acquisition and disposal of company stock and stock options.

Summary

• Patrick Lamy, Senior VP of Commercial Strategy at Akero Therapeutics, reported several transactions involving the company's stock.
• On December 31, 2024, Lamy acquired 234 shares of common stock at a price of $19.686 per share through the company's Employee Stock Purchase Plan.
• On January 27, 2025, Lamy exercised stock options to acquire 4,000 shares at $19.87 per share.
• Also on January 27, 2025, Lamy sold 5,000 shares at $57.03 per share.
• Following these transactions, Lamy beneficially owns 33,492 shares of common stock and 79,182 stock options.

Sentiment

Score: 6

Explanation: The document reflects routine executive stock transactions, which are neither particularly positive nor negative. The use of a pre-arranged trading plan mitigates any potential negative sentiment.

Positives

• The acquisition of shares through the Employee Stock Purchase Plan indicates Lamy's participation in company programs.
• The exercise of stock options suggests a belief in the company's future prospects.

Negatives

• The sale of 5,000 shares could be interpreted as a reduction in Lamy's stake in the company, although this is part of a pre-arranged trading plan.

Risks

• Executive stock transactions can sometimes be perceived negatively by the market, even when part of a pre-planned strategy.
• Fluctuations in the stock price could impact the value of Lamy's holdings.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies and are often part of compensation packages and personal financial planning. The use of a Rule 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.

Comparison to Industry Standards

• The use of a Rule 10b5-1 trading plan is a common practice among executives at publicly traded companies, such as those in the biotechnology sector like Gilead Sciences or Amgen, to manage their stock transactions.
• Employee Stock Purchase Plans are also a standard benefit offered by many companies, including those in the pharmaceutical industry like Regeneron or Vertex Pharmaceuticals, allowing employees to acquire shares at a discount.
• The vesting schedule of the stock options, with 48 equal monthly installments, is a typical vesting structure seen in many companies, including those in the tech sector like Apple or Microsoft.

Stakeholder Impact

• The transactions may have a minor impact on shareholders, as they reflect the actions of a company executive.
• The use of a pre-arranged trading plan helps to ensure transparency and avoid potential concerns about insider trading.

Key Dates

Keywords

Akero Therapeutics, stock transactions, insider trading, Form 4, employee stock purchase plan, stock options, Rule 10b5-1, Patrick Lamy